BIOMECITE IS DEVELOPING A DIAGNOSTIC PLATFORM BASED ON THE MICROBIOME SIGNATURE
Biomecite Diagnostics was created through a collaboration of InnovateTech Ventures, the University of Maryland Baltimore, and TEDCO (the Technology Development Corporation of the state of Maryland.)
In the Fall of 2014, InnovateTech was awarded a TEDCO Phase I/II Maryland Innovation Initiative (MII) grant to explore the viability of a start up based upon patent pending technology created by Dr. Florian Fricke and Dr. James White at the University of Maryland, Baltimore.
Following positive findings from that study, InnovateTech created Biomecite Diagnostics, LLC in December, 2014 and in March, successfully applied for $100,000 in Phase III funding from the same TEDCO program. These funds are being used to run a Proof of Concept Study that is being managed by CSSi LifeSciences,™ a Maryland based organization.
InnovateTech Ventures is a “Venture Creation” firm that brings together seed funding, high potential university technologies and experienced management teams to create promising new startups.
Chief Executive Officer
Before Dr. Hoke took over at Biomecite, he was the Chief Operating Officer at Theranostics Health. He has served as Executive Vice President and Chief Scientific Officer at Dyad Pharmaceutical (2003-2009). He managed the preclinical development of Dyad’s lead therapeutics. Prior to Dyad, while Vice President Research and Development at Gene Logic (1998-2003), Dr. Hoke led research and development efforts on a number of platform technologies. He was Vice President at Genetic MediSyn (1993-1998), the drug discovery arm of SyntheCell. Dr. Hoke was employed at Isis Pharmaceuticals (1989-1993). Prior to Isis, he worked as a joint appointee in the Departments of Molecular Pharmacology and Investigative Toxicology at SmithKline and French Research Laboratories (1986-1989). Dr. Hoke received his doctorate (1986) Biochemistry at the Medical College of Virginia, Virginia Commonwealth University; a B.S. in biology (1974) from Virginia Polytechnic Institute and State University; and a master’s degree in biology (1979) from Virginia Commonwealth University.
Jennifer Murphy is retired from a long career at George Mason University and other area universities. After retirement, she joined InnovateTech as a senior advisor and welcomed the opportunity to be a co-founder of Biomecite Diagnostics. At Mason, Ms. Murphy was involved in the creation of 18 companies. Of those, six remain healthy, have funding, and a clear path to market and five have products and/or services in the commercial marketplace. After retirement, Ms. Murphy became a Senior Advisor for InnovateTech Ventures and has consulted for PatentServices.com and for SRI International. She is on the Advisory Board for TechCast, a George Washington University startup. Ms. Murphy is serving on her third “Transition Plan” panel at the “Congressionally Directed Medical Research Program” (CDMRP).
Dr. James Robert White
Dr. James Robert White serves as President of Biomecite Diagnostics and is co-inventor of the technology licensed by the company for biomarker discovery. His research focuses on the development of novel statistical methods for analysis of high-throughput DNA sequence datasets in the context of the human microbiome, infectious disease and cancer genomics. A contributor to the Human Microbiome Project, Dr. White has more than 35 published papers in peer-reviewed journals. He received his B.S. from the University of Maryland in Mathematics and Ph.D. from University of Maryland in Applied Mathematics and Scientific Computation.
Dr. William E. Gannon, Jr., M.D.
Dr. Gannon serves as Chief Scientific Officer & Medical Director for Capital City Technical Consulting (CCTC) in Washington, DC and is the CMO for Biomecite. In addition to receiving his medical training and clinical work at Ross University, Case Western Reserve and George Washington University, Dr. Gannon obtained an M.B.A. at George Washington University in 1988 and has since built a wealth of experience in the management of clinical trials including designing the trials and building operational teams to ensure their successful completion. Dr. Gannon has held positions in multinational Clinical Research Organizations, medical device, biotech and pharmaceutical firms. In his most recent position prior to CCTC, Inc., Dr. Gannon served as Vice President – Clinical & Medical Affairs in the biotechnology arena. Dr. Gannon’s primary focus has been on oncology therapeutic and diagnostic applications, but possesses a board range of experience across therapeutic categories. Dr. Gannon has managed clinical trials and operations as well as the design, corporate and regulatory strategies, regulatory submissions and execution of Phase I through Phase IV clinical trials in the U.S., Europe and Asia. Additionally, Dr. Gannon is involved in philanthropy in the Washington, DC area and currently serves on the Board of Directors for the Engineering World Health Organization and The Foundation for Sickle Cell Research.
Dr. Florian Fricke
Dr. Fricke is a co-inventor of the technology being commercialized by Biomecite. Dr. Fricke received his Ph.D. under the mentorship of Prof. Dr. Gerhard Gottschalk in 2005 at the Georg-August University in Göttingen, Germany, where he was introduced to microbial genomics and applied bioinformatics. He continued to work in this field as a post-doc at The Institute for Genomic Research (TIGR) in Rockville, Maryland, in the group of Dr. Jacques Ravel. In 2007, he moved to the newly founded Institute for Genome Sciences at the University of Maryland where he became Assistant Professor in the Department of Microbiology & Immunology in 2010. In 2014, Dr. Fricke became a professor of Nutrigenomics at the University of Hohenheim in Germany.
Jim held various positions in academic oncology and cancer research before co-founding and serving as CEO of ProED, a healthcare services and drug development company. His team was responsible for over 50 successful NDA/BLA and EMA applications and defenses for various drugs, biologics, and diagnostic tests, including over 150- 510(k) submissions. In addition, Jim has played a major role in the commercial success and launch of over 400 drugs and biologics. Jim established a paradigm for helping clients create a strategic pathway from discovery to commercialization that resulted in a reduction of development time, costs and resources. Jim’s academic and medical experience includes Director and Administrator for the Department of Experimental Therapeutics at the Cleveland Clinic Cancer Center, Associate Professor of Medical-Surgical Nursing at the Case Western Reserve University, Lecturer for Oncology at the Cleveland State University, and Research Manager of Hematology and Medical Oncology at the Cleveland Veterans Administration Medical Center Research Division.
In addition to providing legal services to the technology community for almost twenty years, Rob is also a technology entrepreneur and advisor. His straightforward style and practical business approach have consistently assisted clients to achieve their goals and objectives. His experience in co-founding and running two companies equips him with a unique perspective among attorneys on how legal services fit within an entire business. Rob also plays an active role in the community, assisting several legal and non-legal community groups.